Aegerion Pharmaceuticals Inc.

(AEGR) Trade

By |

Profile

Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada.

Contact Information

Website: www.aegerion.com
Main Phone: +1 617 500-7867
Address: One Main Street
Address 2: Suite 800
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02142

Issuer Information

Exchange: NGS
CEO: Mary T. Szela
Employees: 318
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Aegerion Pharmaceuticals, Inc. was incorporated in February 2005. The Company is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company currently operates in one business segment focusing on the development and commercialization of its product, lomitapide. The product, lomitapide, received marketing approval, under the brand name JUXTAPID (lomitapide) capsules ("JUXTAPID"). It is an adjunct to a low-fat diet and other lipid-lowering treatments, including low-density lipoprotein ("LDL") apheresis where available, to reduce low-density lipoprotein cholesterol ("LDL-C"), total cholesterol ("TC"), apolipoprotein B ("apo B") and non-high-density lipoprotein cholesterol ("non-HDL-C") in adult patients with homozygous familial hypercholesterolemia ("HoFH"). Lomitapide is also approved for the treatment of HoFH in Norway, Iceland, Mexico and Canada.

Contact Information

Website: www.aegerion.com
Main Phone: +1 617 500-7867
Address: One Main Street
Address 2: Suite 800
State: MA
City / Town: Cambridge
Country: USA
Postal Code: 02142

Issuer Information

Exchange: NGS
CEO: Mary T. Szela
Employees: 318
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume 0 52 Wk Hi 10.86 52 Wk Low 1.24
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 29,545,088.00 EPS (TTM) -5.98 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
Mark J. Fitzpatrick 1,000
Marc D. Beer 1,000
Marc D. Beer 1,000
Marc D. Beer 1,000
Marc D. Beer 1,000
Marc D. Beer 1,000
Anne M. Vanlent 1,000
Anne M. Vanlent 1,000
Marc D. Beer 1,000
Anne M. Vanlent 1,000
Last 10 Sell Shares
Craig Fraser 1,000
Craig Fraser 1,000
Craig Fraser 1,000
Mark Sumeray 1,000
Mark Sumeray 1,000
Mark Sumeray 1,000
Mark Sumeray 1,000
Mark Sumeray 1,000
Mark J. Fitzpatrick 1,000
Mark J. Fitzpatrick 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 1.5 1.5 1.5 1.5
Low Target Price Estimate 1.5 1.5 1.5 1.5
Mean Target Price Estimate 1.5 1.5 1.5 1.5
Standard Deviation 0 0 0 0
Date of Most Recent Estimate 11/15/16 11/15/16 11/15/16 11/15/16
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 2 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 3 3 3 3